Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by López de Mesa, R.
Right arrow Articles by Patiño-García, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by López de Mesa, R.
Right arrow Articles by Patiño-García, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Mutagenesis, Vol. 17, No. 2, 171-175, March 2002
© 2002 UK Environmental Mutagen Society/Oxford University Press


REVIEW

Measurement and analysis of the chemotherapy-induced genetic instability in pediatric cancer patients

Reyes López de Mesa, Adela López de Ceráin Salsamendi1, Luis Sierrasesúmaga Ariznabarreta, Ma José Calasanz Abínzano2 and Ana Patiño-García,3

Laboratory and Department of Pediatrics, 1 Department of Toxicology and 2 Department of Genetics, University of Navarra, E-31080 Pamplona, Spain

Bleomycin sensitivity has been proven to be a useful biomarker for environmental carcinogenesis and tumor genetic instability. We have previously reported a significant increase in the chromosomal aberrations induced by chemotherapy regimens. This study aimed to test whether there is an inherent increased genetic instability in cancer patients at diagnosis, to determine the increase and time course of the chemotherapy-induced instability and to test whether bleomycin sensitivity can be used as a predictor of tumor evolution or relapse. The analysis included 99 pediatric cancer patients with four different tumor types (Ewing's sarcoma, osteosarcoma, lymphoma and CNS tumors) and 25 controls. Blood samples (n = 171) were obtained before and at the end of treatment, during clinical remission and at relapse and bleomycin tests on lymphocyte cultures were performed. We detected a significant increase (P = 0.004) in mutagen sensitivity in patients at the end of treatment compared with untreated patients, regardless of the tumor type. In both the longitudinal and cross-sectional analyses maximal and similar values of mutagen sensitivity were found in patients during treatment (1.84 ± 0.82) and at relapse (1.78 ± 0.52); minimum and similar values were found in controls (0.93 ± 0.23), untreated patients (1.15 ± 0.65) and in those who had fulfilled the chemotherapy protocols for at least 2 years before their sample was collected (1.09 ± 0.53). From this preliminary data we can conclude that cytostatic drugs induce a transient increase in chromosomal instability in pediatric cancer patients that can be monitored by bleomycin-induced sensitivity tests and that the genetic instability indices should be further investigated as predictors of relapse.

3 To whom correspondence should be addressed. Tel: +34 948 425653; Fax: +34 948 425652; Email: apatigar{at}unav.es


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.